Endometrial receptivity indicators in patients with adenomyosis
DOI: 10.32364/2618-8430-2025-8-3-1
Yu.E. Dobrokhotova1, E.I. Borovkova1, T.N. Belousova2, D.S. Safina1
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2Vidnoye Perinatal Center, Vidnoye, Russian Federation
Aim: to improve endometrial receptivity by exogenous cytokinotherapy in patients with adenomyosis.
Materials and Methods: 67 patients of reproductive age divided into 2 groups were enrolled in a prospective study. A study group included 27 patients with adenomyosis, and a control one included 40 patients without it. Age, body mass index, somatic and gynecological diseases were comparable in these subjects. At the first stage, endometrial receptivity measured by pipelle biopsy performed on Day 19–24 of a menstrual cycle was evaluated. At the second stage, the study group received a cytokinotherapeutic agent, 25 units, per 1 suppository p.v. q.h.s. within 2 months (except for days of menstrual bleeding). Immediately after the end of the treatment regimen, endometrial sampling was repeated, and endometrial receptivity was assessed. An immunohistochemical testing was performed to assess a number of pinopodes (%), as well as expression of estrogen and progesterone receptors in the glandular epithelium and the stroma.
Results: adenomyosis was associated with a decreased number of pinopodes (by 1.3 times), as well as an increased level of estrogen (by 2.6 and 2.3 times in the stroma and the glandular epithelium, respectively) and progesterone receptors (by 1.5 and 1.2 times in the stroma and the glandular epithelium, respectively). After the cytokinotherapy, a significant increase in a number of pinopodes (from 41.5 to 45.3%, p=0.02), as well as in expression of estrogen (from 176.4 to 192.2 [p=0.02] in the stroma; from 170.8 to 189.3 [p=0.01] in the epithelium) and progesterone receptors (from 190.1 to 236.4 [p=0.01] in the stroma; from 127.8 to 179.7 [p=0.01] in the epithelium) was reported.
Conclusion: 2-month exogenous cytokinotherapy helps to improve endometrial receptivity.
Keywords: endometrial receptivity, adenomyosis, receptors, estrogen, progesterone, pinopodes, cytokinotherapy.
For citation: Dobrokhotova Yu.E., Borovkova E.I., Belousova T.N., Safina D.S. Endometrial receptivity indicators in patients with adenomyosis. Russian Journal of Woman and Child Health. 2025;8(3):186–191 (in Russ.). DOI: 10.32364/2618-8430-2025-8-3-1
About the authors:
Yulia E. Dobrokhotova — Dr. Sc. (Med.), Professor, Head of the Department of Obstetrics and Gynecology of the Institute of Surgery, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117513, Russian Federation; ORCID iD 0000-0002-7830-2290
Ekaterina I. Borovkova — Dr. Sc. (Med.), Associate Professor, Professor of the Department of Obstetrics and Gynecology of the Institute of Surgery, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117513, Russian Federation; ORCID iD 0000-0001-7140-262X
Tamara N. Belousova — C. Sc. (Med.), Chief Physician of Vidnoye Perinatal Center; 17, Zavodskaya str., Vidnoye, 142700, Russian Federation; ORCID iD 0000-0003-3804-7691
Dariya S. Safina — Clinical Resident of the Department of Obstetrics and Gynecology, Faculty of the Institute of Surgery, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117513, Russian Federation; ORCID iD 0000-0001-6598-9310
Contact information: Ekaterina I. Borovkova, e-mail: Katyanikitina@mail.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 28.05.2025.
Revised 24.06.2025.
Accepted 17.07.2025.
2. Upson K., Missmer S.A. Epidemiology of Adenomyosis. Semin Reprod Med. 2020;38(2–03):89–107. DOI: 10.1055/s-0040-1718920
3. Sztachelska M., Ponikwicka-Tyszko D., Martínez-Rodrigo L. et al. Functional Implications of Estrogen and Progesterone Receptors Expression in Adenomyosis, Potential Targets for Endocrinological Therapy. J Clin Med. 2022;11(15):4407. DOI: 10.3390/jcm11154407
4. Шкляр А.А., Адамян Л.В., Коган Е.А. и др. Рецепторный статус эндометриоидных гетеротопий как критерий назначения гормональной терапии при узловой и диффузной формах аденомиоза. Проблемы репродукции. 2015;21(2):88–93. DOI: 10.17116/repro201521288-93Shklyar A.A., Adamyan L.V., Kogan E.A. et al. Receptor status of endometrioid heterotopias as the indication for hormonal therapy of nodular and diffuse forms of adenomyosis. Russian Journal of Human Reproduction. 2015;21(2):88–93 (in Russ.). DOI: 10.17116/repro201521288-93
5. Zeng Y.Y., Guan Y.G., Li K.Y. Role of estrogen, estrogen receptors, and aromatase in the pathogenesis of uterine adenomyosis. Nan Fang Yi Ke Da Xue Xue Bao. 2017;37(3):383–387. DOI: 10.3969/j.issn.1673-4254.2017.03.18
6. Mehasseb M., Panchal R., Taylor A. et al. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril. 2011;95(7):2228–2235, 2235.e1. DOI: 10.1016/j.fertnstert.2011.02.051
7. Inoue S., Hirota Y., Ueno T. et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019;10(1):5785. DOI: 10.1038/s41467-019-13708-y
8. Bourdon M., Santulli P., Oliveira J. et al. Focal adenomyosis is associated with primary infertility. Ferti Steril. 2020;114(6):1271–1277. DOI: 10.1016/j.fertnstert.2020.06.018
9. Доброхотова Ю.Э., Боровкова Е.И., Зайдиева З.С. и др. Повышение эффективности терапии пациенток с хроническим эндометритом. Вопросы гинекологии, акушерства и перинатологии. 2022;21(4):92–98. DOI: 10.20953/1726-1678-2022-4-92-98Dobrokhotova Yu.E., Borovkova E.I., Zaydieva Z.S. et al. Improving the effectiveness of therapy for chronic endometritis. Gynecology, Obstetrics and Perinatology. 2022;21(4):92–98 (in Russ.). DOI: 10.20953/1726-1678-2022-4-92-98
10. Доброхотова Ю.Э., Ганковская Л.В., Боровкова Е.И., Нугуманова О.Р. Экзогенная цитокинотерапия в лечении пациенток с хроническим эндометритом. Акушерство и гинекология. 2021;2:125–132. DOI: 10.18565/aig.2021.2Dobrokhotova Yu.E., Gankovskaya L.V., Borovkova E.I., Nugumanova O.R. Exogenous cytokine therapy in the treatment of patients with chronic endometritis. Obstetrics and Gynecology. 2021;2:125–132 (in Russ.). DOI: 10.18565/aig.2021.2
11. Maclean A., Tipple L., Newton E., Hapangama D.K. Hormone receptor profile of ectopic and eutopic endometrium in adenomyosis: a systematic review. Hum Reprod Open. 2025;2025(1):hoaf002. DOI: 10.1093/hropen/hoaf002
12. Sztachelska M., Ponikwicka-Tyszko D., Martınez-Rodrigo L. et al. Functional Implications of Estrogen and Progesterone Receptors Expression in Adenomyosis, Potential Targets for Endocrinological Therapy. J Clin Med. 2022;11:4407. DOI: 10.3390/jcm11154407
13. Etrusco A., Barra F., Chiantera V. et al. Current medical therapy for adenomyosis: from bench to bedside. Drugs. 2023;83:1595–1611. DOI: 10.1007/s40265-023-01957-7
14. Bulun S.E., Yildiz S., Adli M. et al. Endometriosis and adenomyosis: shared pathophysiology. Fertil Steril. 2023;119:746–750. DOI: 10.1016/j.fertnstert.2023.03.006
15. Samartzis N., Kalaitzopoulos D.R., Noske A. et al. The immunohistochemical expression of GPER and classical sex hormone receptors differs in adenomyosis and eutopic endometrium. J Reprod Immunol. 2023;156:103795. DOI: 10.1016/j.jri.2023.103795
16. Khan K.N., Fujishita A., Kitajima M. et al. Biological differences between functionalis and basalis endometria in women with and without adenomyosis. Eur J Obstet Gynecol Reprod Biol. 2016;203:49–55. DOI: 10.1016/j.ejogrb.2016.05.012
This work is licensed under a Creative Commons «Attribution» 4.0 License.
